Vaccination with a modified vaccinia virus Ankara (MVA)-vectored HIV-1 immunogen induces modest vector-specific T cell responses in human subjects

Vaccine

Volumn 28, Issue 45, 2010, Pages 7306-7312

  Howles, Sarah ^a   Guimarães Walker, Ana ^a   Yang, Hongbing ^a   Hancock, Gemma ^a   di Gleria, Katalin ^a   Tarragona Fiol, Tony ^b   Hayes, Peter ^b   Gilmour, Jill ^b   Bridgeman, Anne ^a   Hanke, Tomáš ^a   McMichael, Andrew ^a   Dorrell, Lucy ^a  

^a JOHN RADCLIFFE HOSPITAL   (United Kingdom)

^b CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

Author keywords

Clinical trial; HIV 1 vaccine; Human; Modified vaccinia virus Ankara (MVA); T cell

Indexed keywords

GAMMA INTERFERON; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; SMALLPOX VACCINE; UNCLASSIFIED DRUG; VACCINIA VIRUS ANKARA VECTOR; VIRUS VECTOR;

ADULT; ARTICLE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AIDS VACCINES; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; EPITOPES, T-LYMPHOCYTE; GENETIC VECTORS; HIV INFECTIONS; HIV SERONEGATIVITY; HIV-1; HUMANS; IMMUNITY, CELLULAR; IMMUNIZATION, SECONDARY; INTERFERON-GAMMA; MIDDLE AGED; T-LYMPHOCYTES; VACCINIA VIRUS; YOUNG ADULT;

EID: 77957752730     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2010.08.077     Document Type: Article

References (28)

1. Duerr A., Wasserheit J.N., Corey L. HIV vaccines: new frontiers in vaccine development. Clin Infect Dis 2006, 43(4):500-511.
2. McMichael A.J. HIV vaccines. Annu Rev Immunol 2006, 24(1):227-255.
3. McElrath M.J., De Rosa S.C., Moodie Z., Dubey S., Kierstead L., Janes H., et al. HIV-1 vaccine-induced immunity in the test-of-concept Step Study: a case-cohort analysis. Lancet 2008, 372(9653):1894-1905.
4. Tatsis N., Fitzgerald J.C., Reyes-Sandoval A., Harris-McCoy K.C., Hensley S.E., Zhou D., et al. Adenoviral vectors persist in vivo and maintain activated CD8+ T cells: implications for their use as vaccines. Blood 2007, 110(6):1916-1923.
5. Hanke T., McMichael A.J., Dennis M.J., Sharpe S.A., Powell L.A.J., McLoughlin L., et al. Biodistribution and persistence of an MVA-vectored candidate HIV vaccine in SIV-infected rhesus macaques and SCID mice. Vaccine 2005, 23(12):1507-1514.
6. Smith C.L., Mirza F., Pasquetto V., Tscharke D.C., Palmowski M.J., Dunbar P.R., et al. Immunodominance of poxviral-specific CTL in a human trial of recombinant-modified vaccinia Ankara. J Immunol 2005, 175(12):8431-8437.
7. Harro C.D., Robertson M.N., Lally M.A., O'Neill L.D., Edupuganti S., Goepfert P.A., et al. Safety and immunogenicity of adenovirus-vectored near-consensus HIV type 1 clade B gag vaccines in healthy adults. AIDS Res Hum Retroviruses 2009, 25(1):103-114.
8. Gudmundsdotter L., Nilsson C., Brave A., Hejdeman B., Earl P., Moss B., et al. Recombinant modified vaccinia Ankara (MVA) effectively boosts DNA-primed HIV-specific immune responses in humans despite pre-existing vaccinia immunity. Vaccine 2009, 27(33):4468-4474.
9. Harrer E., Bäuerle M., Ferstl B., Chaplin P., Petzold B., Mateo L., et al. Therapeutic vaccination of HIV-1-infected patients on HAART with a recombinant HIV-1 NEF-expressing MVA: safety, immunogenicity and influence on viral load during treatment interruption. Antiviral Ther 2005, 10:285-300.
10. Autran B., Murphy R.L., Costagliola D., Tubiana R., Clotet B., Gatell J., et al. Greater viral rebound and reduced time to resume antiretroviral therapy after therapeutic immunization with the ALVAC-HIV vaccine (vCP1452). AIDS 2008, 22(11):1313-1322.
11. Goonetilleke N., Moore S., Dally L., Winstone N., Cebere I., Mahmoud A., et al. Induction of multifunctional HIV-1-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA- and modified vaccinia virus Ankara-vectored vaccines expressing HIV-1 gag coupled to CD8+ T cell epitopes. J Virol 2006, 80(10):4717-4728.
12. Dorrell L., Yang H., Ondondo B., Dong T., de Gleria K., Suttill A., et al. Expansion and diversification of virus-specific T cells following immunisation of HIV-1-infected individuals with a recombinant modified vaccinia virus Ankara/HIV-1 gag vaccine. J Virol 2006, 80(10):4705-4716.
13. Guimaraes-Walker A., Mackie N., McCormack S., Hanke T., Schmidt C., Gilmour J., et al. Lessons from IAVI-006, a phase I clinical trial to evaluate the safety and immunogenicity of the pTHr.HIVA DNA and MVA.HIVA vaccines in a prime-boost strategy to induce HIV-1 specific T-cell responses in healthy volunteers. Vaccine 2008, 26(51):6671-6677.
14. Hanke T., Goonetilleke N., McMichael A., Dorrell L. Clinical experience with plasmid DNA- and modified vaccinia virus Ankara-vectored human immunodeficiency virus type 1 clade A vaccine focusing on T-cell induction. J Gen Virol 2007, 88:1-12.
15. Yang H., Guimaraes-Walker A., Hibbs S., Dong T., Stacey A., Borrow P., et al. Interleukin-10 responses to therapeutic vaccination during highly active antiretroviral therapy and after analytical therapy interruption. AIDS 2009, 23(16):2226-2230.
16. Slyker J.A., Lohman B.L., Mbori-Ngacha D.A., Reilly M., Wee E.G., Dong T., et al. Modified vaccinia Ankara expressing HIVA antigen stimulates HIV-1-specific CD8 T cells in ELISpot assays of HIV-1 exposed infants. Vaccine 2005, 23(38):4711-4719.
17. Jing L., Chong T.M., McClurkan C.L., Huang J., Story B.T., Koelle D.M. Diversity in the acute CD8 T cell response to vaccinia virus in humans. J Immunol 2005, 175(11):7550-7559.
18. Calvo-Calle J.M., Strug I., Nastke M.D., Baker S.P., Stern L.J. Human CD4+ T cell epitopes from vaccinia virus induced by vaccination or infection. PLoS Pathog 2007, 3(10):1511-1529.
19. Meyer R.G., Graf C., Britten C.M., Huber C., Wölfel T. Rapid identification of an HLA-B*1501-restricted vaccinia peptide antigen. Vaccine 2007, 25(24):4715-4722.
20. Drexler I., Staib C., Kastenmuller W., Stevanovic S., Schmidt B., Lemonnier F.A., et al. Identification of vaccinia virus epitope-specific HLA-A*0201-restricted T cells and comparative analysis of smallpox vaccines. Proc Natl Acad Sci USA 2003, 100(1):217-222.
21. Terajima M., Cruz J., Raines G., Kilpatrick E.D., Kennedy J.S., Rothman A.L., et al. Quantitation of CD8+ T cell responses to newly identified HLA-A*0201-restricted T cell epitopes conserved among vaccinia and variola (smallpox) viruses. J Exp Med 2003, 197(7):927-932.
22. Terajima M., Orphin L., Leporati A.M., Pazoles P., Cruz J., Rothman A.L., et al. Vaccinia virus-specific CD8(+) T-cell responses target a group of epitopes without a strong immunodominance hierarchy in humans. Hum Immunol 2008, 69(12):815-825.
23. Sidney J., Southwood S., Sette A. Classification of A1- and A24-supertype molecules by analysis of their MHC-peptide binding repertoires. Immunogenetics 2005, 57(6):393-408.
24. Combadiere B., Boissonnas A., Carcelain G., Lefranc E., Samri A., Bricaire F., et al. Distinct time effects of vaccination on long-term proliferative and IFN-gamma-producing T cell memory to smallpox in humans. J Exp Med 2004, 199(11):1585-1593.
25. Oseroff C., Kos F., Bui H.H., Peters B., Pasquetto V., Glenn J., et al. HLA class I-restricted responses to vaccinia recognize a broad array of proteins mainly involved in virulence and viral gene regulation. Proc Natl Acad Sci USA 2005, 102(39):13980-13985.
26. Letourneau S., Im E.J., Mashishi T., Brereton C., Bridgeman A., Yang H., et al. Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS ONE 2007, 2(10):e984.
27. Hill A.V., Reyes-Sandoval A., O'Hara G., Ewer K., Lawrie A., Goodman A., et al. Prime-boost vectored malaria vaccines: progress and prospects. Hum Vaccin 2010, 6(1):78-83.
28. Geels M.J., Dubey S.A., Anderson K., Baan E., Bakker M., Pollakis G., et al. Broad cross-clade T-cell responses to gag in individuals infected with human immunodeficiency virus type 1 non-B clades (A to G): importance of HLA anchor residue conservation. J Virol 2005, 79(17):11247-11258.